Wise Practice of Chinese Hemodialysis (WISHES)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30,000
- 试验地点
- 2
- 主要终点
- Patient survival of HD patients
研究概览
简要总结
The investigators are registering all HD patients at recruited hospitals and developing a HD database in China. Patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.
详细描述
The investigators are registering all end stage renal disease (ESRD) patients receiving hemodialysis (HD) treatment, and developing a HD database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum, urine, and access patency), complications, drug information and scores of quality of life at the baseline will be collected. Patients will be follow-up every 3 month, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to peritoneal dialysis, hospitalization, access failure,etc. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •End stage renal disease patients receiving hemodialysis treatment.
排除标准
- 未提供
研究组 & 干预措施
Hemodialysis patients
End stage renal disease patients receiving hemodialysis treatment
干预措施: No intervention (Other)
结局指标
主要结局
Patient survival of HD patients
时间窗: 10 years
次要结局
- Patency rate of access for HD patients(10 years)
- Quality of life evaluated using SF36 scale for HD patients(10 years)
研究者
Xue Qing Yu
Professor
Sun Yat-sen University
